Alzheimer's Disease Research Paper

Alzheimer disease (AD) is the most common cause of dementia in the elderly, accounting for 65–70% of all cases (Jellinger, Janetzky, Attems, & Kienzl, 2008). The other dementias are of the Parkinson 's group, the fronto-temporal group and the vascular group. The total worldwide yearly costs for the treatment and care of patients suffering from dementia are estimated to be around 250 billion US dollars. The lifetime risk for AD between the ages of 65 and 100 is 33% for men and 45% for women with an annual increase of 1–2% in the seventh decade to almost 60% in the 10th decade with doubling every 5 years (Jellinger et al., 2008). AD is incurable, and thus represents a major public health problem. AD represents a challenge to humanity due to its relatively recent discovery, progressive nature of the illness, and complex diagnosis.

Alzheimer’s disease (AD), a form of degenerative, fatal dementia, is characterized by progressive cognitive decline. While AD is the most common form of dementia, its prevalence has only recently been recognized. When Alois Alzheimer first described the sequence of changes in 1907, physicians believed the disease to be an extremely rare, mid-life condition. It wasn’t until the 1970’s that the same types of changes were shown to occur in both late- and early-onset forms (Cavanaugh et.al. 2008). As such, almost all knowledge of AD has been learned within the past several decades, with new discoveries being reported almost daily. It is now estimated that Alzheimer’s accounts for as many as 60% of all dementias and affects more than 500,000

Alzheimer’s disease is a complex illness that affects the brain tissue directly and undergoes gradual memory and behavioral changes which makes it difficult to diagnose. It is known to be the most common form of dementia and is irreversible. Over four million older Americans have Alzheimer’s, and that number is expected to triple in the next twenty years as more people live into their eighties and nineties. (Johnson, 1989). There is still no cure for Alzheimer’s but throughout the past few years a lot of progress has been made.

Alzheimer’s disease (AD) is a progressive and fatal form of dementia, frequently seen in the elderly altering their cognition, thought process and behavior. AD is reported in about half of patients that have a dementia diagnosis; one study states that about 10.3% of the population over 65 years is affected by dementia with an increase to almost 50% over the age of 8 (Beattie, 2002). Alzheimer’s disease is not a normal part of the aging process in humans, but rather found in a group of diseases that affect the brain leading to a decline in mental and physical control. AD when diagnosed has a very slow and gradual course, initially affecting the individual’s short term memory (Beattie, 2002). Alzheimer’s disease is the 6th leading cause of death, affecting more than five million people in the United States and is also one of the most common forms of dementia. Dementia can be defined as a disorder of progressive cognitive impairment severe enough to affect daily functions of an individual’s life (Fillit, et al., 2002).

As AD is a progressive disease with no currently known cure, all current treatments are aimed at slowing the progression of the disease; these treatments have been available since 1993 (Geldmacher et al., 2011). The desired

Although Alzheimer’s Disease (AD) is the most widely known cause of dementia in the elderly population, there are many other explanations and clinical diagnoses that

Alzheimer’s disease (AD) is a form of dementia that causes problems with memory, thinking, and behavior. AD typically involves the development of a progressive neuropsychiatric disorder that is characterized by gradual memory impairment, loss of acquired skills and emotional disturbances (Lee, Y. J., Han, S. B., Nam, S. Y., Oh, K. W., & Hong, J. T.). Every 67 seconds an individual in the United States develops AD. AD is the sixth leading cause of death in the United States. There are 5.3 million Americans diagnosed with AD (Latest Alzheimer's Facts and Figures). AD is one of the few degenerative diseases that cannot be prevented, stopped, or cured (Latest Alzheimer's Facts and Figures). Post-mortem examination of the brain of AD patients usually

“What is Alzheimer’s disease (AD)?” Alzheimer’s disease is the most common form of dementia that affects an individual’s memory, cognition, and behavior disturbances that ultimately diminishes their quality of life.1-2 Dementia is not a specific disease it is a general term for a variety of symptoms that affect memory and intellectual thinking that causes difficulty in our tasks of daily living.(5) The confusion between these two terms is extraordinary. It’s helpful to think of dementia as the symptom and to think of AD as the cause of that symptom. Although, there are many causes of dementia for the purpose of this paper, Alzheimer’s will be the only one discussed.

Early-onset Alzheimer’s is a rare, but fast stage of Alzheimer’s disease. According to Glenn E. Smith, Ph.D., a neuropsychologist at Mayo Clinic, in Rochester, Minn. (2014), Early-onset Alzheimer’s is an uncommon form of dementia that strikes about 5 percent of patients with symptoms before the age of 65. This form of Alzheimer’s has been known to develop between the ages 30 and 40, but that’s very uncommon (Smith 2014). Scientists do not have an explanation of why people get the disease younger than others. Early-onset Alzheimer’s that is hereditary in family members is connected to three different genes that differ from the APOE gene that can increase your risk of Alzheimer’s in general (Smith 2014). The innate conduit of inheritance is much stronger in early-onset Alzheimer’s (Smith 2014). If one has a genetic mutation

It is a disease that we haven’t cured yet but instead have only come up and still coming up with treatment strategies to alleviate its symptoms. AD was first described in 1906 by a German psychiatrist by the name of Alois Alzheimer whilst he was performing a histophathologic study of his patient’s brain, a patient who had been suffering from dementia. His patient’s brain’s autopsy brought to light the presence of two types of lesions, which are senile plaques and neurofibrillary tangles. He saw a visible difference in the brain tissue for it was severely damaged by these lesions. Since then, our knowledge of AD’s cellular and molecular alterations has increased and we have come up with various hypotheses for AD that may soon help in developing effective preventative and therapeutic strategies. One of the most prevailing hypotheses that have already leaded to a number of therapeutic approaches is the amyloid cascade hypothesis. Hence, the following essay will explore the pathology of the amyloid cascade hypothesis and the evidence for and against it. It will also touch upon current progress in clinical trials that test the

Alzheimer's disease primarily affects elderly patients, although some patients with a specific genetic makeup develop early-onset

However, some believed that Alzheimer’s disease may have been caused by a gene mutation that is carried from one parent to an adolescent. When genes such as APP, PSEN1, or PSEN2 are altered, then an abundant amounts of toxic protein fragment known as amyloid plaques can begin to build within the brain, which leads towards a possibility of dead nerve cells, and the progressing signs and symptoms of this particular disorder. Genetic testing has a very diminutive chance of predicting the disease with a 100 percent of accuracy, nor would results from a blood test would be able to anticipate whether or not one may develop Alzheimer’s disease. It’s difficult to test and identify this disorder because researchers believe that there’s a great number of different factors that may, or may not have its influence in the development, and progression of Alzheimer’s. Despite the difficulties of diagnosing this disorder, there has been a testing known as the APOE that has been currently used within a research to help investigate participants who may have a higher chance of developing Alzheimer’s. APOE has been a great assistance towards researchers and scientists to investigate early brain

One of the most common forms of dementia, Alzheimer’s disease is a brain disorder which impacts activities of daily living through cognitive changes and memory loss. This is a progressive, neurodegenerative disease which is characterized by language deterioration, poor judgment, confusion, restlessness, mood swings, memory loss, and the inability to mentally manipulate visual information. The onset of Alzheimer’s disease generally begins around the mid-60s, but early signs may occur as early as in the early 40s. Some initial symptoms appear as memory decline, but as the illness progresses it starts to destroy cognition, personality, and the individual’s ability to function, along with restlessness and confusion. The severity, type, sequence,

Another clue may be the effects the aging process has on the brain as it is harming the neurons in the brain causing the disease (NIA, 2012). Regardless of the cause, AD is a life altering disease in every aspect of the victim’s life.

Autosomal dominant mutations in APP, PSEN1, or PSEN2 that alter APP processing and the production or self aggregation of Aβ, promote aggregation and accumulation of Aβ in brain causing early-onset AD (Bertram et al., 2010).